Touyun Biotech Group Limited

As of December 31, 2025, Touyun Biotech Group Limited carries a market capitalization of 715.43M, placing it among publicly traded companies globally. Its enterprise value stands at 1.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Touyun Biotech Group Limited has 2.81B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Touyun Biotech Group Limited maintains a current ratio of 0.17, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Touyun Biotech Group Limited's stock has gained approximately 86.30% over the past 52 weeks. The 50-day moving average sits at 0.15, while the 200-day moving average is 0.16.

As of December 31, 2025, Touyun Biotech Group Limited holds 5.06M in cash and equivalents against 413.62M in total debt, resulting in a net debt position of 404.68M. Total book value stands at -51.10M, with working capital of -493.10M providing operational flexibility.

Touyun Biotech Group Limited's most recent stock split took place on August 27, 2019 with a 4:1 split ratio.